Skip to main content
SpringerLink
Log in

Front-line treatment of epithelial ovarian cancer

Focus on the medical oncologists’ perspective

  • Leading Article
  • Published:
American Journal of Cancer

Abstract

Epithelial ovarian cancer is the leading cause of death among the gynecologic malignancies. Over the past decade, advances in the field of ovarian carcinoma have brought an improvement in survival. This article focuses on the front-line management of ovarian cancer. While management of this disease is multidisciplinary and access to a trained gynecologic oncology surgeon is important, this article summarizes the most important advances from the medical oncologists’ perspective. It also reviews the current standard of care based on disease stage, as well as areas of investigation in the front-line treatment of ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Jemal A, Murray T, Ward E, et al. Cancer Statistics, 2005. CA Cancer J Clin 2005; 55: 10–30

    Article  PubMed  Google Scholar 

  2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108

    Article  PubMed  Google Scholar 

  3. Ozols RF, Schwartz PS, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita VT, Hellman S, editors. Cancer: Principles and Practice of Oncology. Philadelphia (PA): Lippincott Williams and Wilkins, 2001: 1597–632

    Google Scholar 

  4. Ozols RF, Rubin SC. In epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, editors. Principles and practice of gynecologic oncology. Philadelphia (PA): Lippincott-Raven Publishers, 1997: 919–86

    Google Scholar 

  5. Dupont NC, Berman ML. Surgical management of epithelial ovarian cancer: a review of the literature. Minerva Ginecol 2004Dec; 56(6): 547–56

    PubMed  CAS  Google Scholar 

  6. vonGruen VE, Daly BJ. Futility: clinical decisions at the end-of-life in women with ovarian cancer. Gynecol Oncol 2005May; 97(2): 638–44

    Article  Google Scholar 

  7. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002; 7Suppl. 5: 20–8

    Article  PubMed  CAS  Google Scholar 

  8. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian carcinoma: results of two prospective randomized trials. N Engl J Med 1990; 322: 1021–8

    Article  PubMed  CAS  Google Scholar 

  9. DiSaia PJ, Creasman WT. Epithelial ovarian cancer. In: Clinical gynecologic oncology. St. Louis (MO): Mosby-Year Book, Inc., 1997: 282–350

  10. Pfisterer J, Lortholary A, Kimmig R, et al. Paclitaxel/carboplatin vs paclitaxel/carboplatin followed by topotecan (TC-Top) in first-line treatment of ovarian cancer FIGO stages IIB-IV: interim results of a Gynecologic Cancer Intergroup Phase III Trial of the AGO Ovarian cancer Study Group and GINECO [abstract]. Proc Am Soc Clin Oncol 2003; 22: 446a

    Article  Google Scholar 

  11. FIGO Committee on Gynecologic Oncology, September 2003. Staging classifications and clinical practice guidelines of gynecologic cancers. Available from URL: http://www.figo.org [Accessed 2005 Aug 10]

  12. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary in volume 25 of the FIGO annual report on the results of treatment in gynecologic cancer. Int J Gynaecol Obstet 2003Oct; 83Suppl. 1: 135–66

    Article  PubMed  Google Scholar 

  13. Griffiths CT. Surgical resection of tumor bulk in primary treatment of ovarian carcinoma. J Natl Cancer Inst Monogr 1975; 42: 101–4

    CAS  Google Scholar 

  14. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with completely resected stage III ovarian cancer: a GOG Study. J Clin Oncol 2003; 21: 3194–200

    Article  PubMed  CAS  Google Scholar 

  15. Young R, Chabner B, Hibbard S, et al. Advanced ovarian carcinoma: a prospective randomized trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 1978; 299: 1261–6

    Article  PubMed  CAS  Google Scholar 

  16. Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 1992; 47: 159–66

    Article  PubMed  CAS  Google Scholar 

  17. Mutch DG. Surgical management of ovarian cancer. Semin Oncol 2002; 29(1 Suppl. 1): 3–8

    Article  PubMed  Google Scholar 

  18. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248–59

    Article  PubMed  Google Scholar 

  19. Eisenkop SM, Spirtos NM, Montag DW, et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992; 47: 203–9

    Article  PubMed  CAS  Google Scholar 

  20. Nguyen HN, Averette HE, Hoskins W, et al. National survey of ovarian carcinoma. Part V: the impact of physician’s specialty on patients’ survival. Cancer 1993; 72: 3663–70

    Article  PubMed  CAS  Google Scholar 

  21. Junor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer 1994; 70: 363–70

    Article  PubMed  CAS  Google Scholar 

  22. Elit L, Bondy SJ, Paszat L, et al. Outcomes in surgery for ovarian cancer. Gynecol Oncol 2002; 87: 260–7

    Article  PubMed  CAS  Google Scholar 

  23. van derBerg MEL, vanLent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis of advanced epithelial ovarian cancer. N Engl J Med 1995; 3332: 629–34

    Google Scholar 

  24. Rose PG, Nerenstone S, Brady M, et al. A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group Study [abstract]. Proc Am Soc Clin Oncol 2002; 21: 802

    Google Scholar 

  25. Vergote IB, DeWever I, Decloedt J, et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 2000; 27: 31–6

    PubMed  CAS  Google Scholar 

  26. Ansquer Y, Leblanc E, Clough K, et al. Neoadjuvant therapy for unresectable ovarian carcinoma: a French multicentre study. Cancer 2001; 91: 2329–34

    Article  PubMed  CAS  Google Scholar 

  27. Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999; 72: 93–9

    Article  PubMed  CAS  Google Scholar 

  28. Vergote I, DeWever I, Tjalma W, et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998; 71: 431–6

    Article  PubMed  CAS  Google Scholar 

  29. Ozols RF, Schwartz PS, Eifel PJ. In Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita VT, Hellman S, editors. Cancer: principles and practice of oncology. Philadelphia (PA): Lippincott Williams and Wilkins, 2001: 1597

    Google Scholar 

  30. Colombo N, Chiari S, Maggioni A, et al. Controversial issues in the management of early epithelial ovarian carcinoma: conservative surgery and the role of adjuvant therapy. Gynecol Oncol 1994; 55: S47–51

    Article  PubMed  CAS  Google Scholar 

  31. Young RC, Brady MF, Nieberg RK, et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin: a Gynecologic Oncology Group Study. J Clin Oncol 2003; 21: 4350–5

    Article  PubMed  CAS  Google Scholar 

  32. Young RC. Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/Carboplatin in early stage ovarian cancer. Semin Oncol 2000; 27(3 Suppl. 7): 8–10

    PubMed  CAS  Google Scholar 

  33. Young RC, Rose G, Lage J. A randomized phase III trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: a GOG Study [abstract]. Gynecol Oncol 2003; 88: 156

    Article  Google Scholar 

  34. Vergote IB, Vergote-DeVos LN, Abeler VM, et al. Randomized trial comparing cisplatin with radioactive phosphorous or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992; 69: 741–9

    Article  PubMed  CAS  Google Scholar 

  35. Trimbos JB, Parmar M, Vergote I, et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95(2): 105–12

    Article  PubMed  Google Scholar 

  36. Colombo N, Guthrie D, Chiari S, et al. International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003; 95: 125–32

    Article  PubMed  Google Scholar 

  37. Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003; 95: 113–25

    Article  PubMed  CAS  Google Scholar 

  38. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique neoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273–9

    PubMed  CAS  Google Scholar 

  39. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a GOG study. J Clin Oncol 1994; 12: 1748–53

    PubMed  CAS  Google Scholar 

  40. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991; 9: 1691–703

    Google Scholar 

  41. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996; 334: 1–6

    Article  PubMed  CAS  Google Scholar 

  42. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699–708

    Article  PubMed  CAS  Google Scholar 

  43. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a GOG study. J Clin Oncol 2000; 18: 106–15

    PubMed  CAS  Google Scholar 

  44. ICON Group, Parmar MKB, Adams M, Balestrino M, et al. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360: 505–15

    Article  Google Scholar 

  45. Bookman MA, McGuire IIIWP, Kilpatrick D, et al. Carboplatin and Paclitaxel in ovarian carcinoma: a phase I study of the GOG. J Clin Oncol 1996; 14: 1895–902

    PubMed  CAS  Google Scholar 

  46. Niejt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084–92

    Google Scholar 

  47. DuBois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 17: 1320–9

    Article  Google Scholar 

  48. Morgan Jr RJ, Alvarez RD, DK Armstrong, et al. NCCN practice guidelines in ovarian cancer. The National Comprehensive Cancer Center Network. VI.2003

  49. Kaye SB, Piccart M, Aapro M, et al. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer: an updated overview. Eur J Cancer 1997Nov; 33(13): 2167–70

    Article  PubMed  CAS  Google Scholar 

  50. Vasey PA. Role of docetaxel in the treatment of newly diagnosed ovarian cancer. J Clin Oncol 2003May 15; 21(10 Suppl.): 136–44

    Article  Google Scholar 

  51. Stuart GC. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol 2003Sep; 90(3 Pt 2): S8–15

    Article  PubMed  CAS  Google Scholar 

  52. Copeland LJ, Bookman MA, Trimble E. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group protocol GOG 182-ICON5. Gynecol Oncol 2003Aug; 90(2 Pt 2): S1–7

    Article  PubMed  CAS  Google Scholar 

  53. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2003May; 4(5): 277–83

    Article  PubMed  CAS  Google Scholar 

  54. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclo phosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950–5

    Article  PubMed  CAS  Google Scholar 

  55. Gadducci A, Camino F, Chiara S, et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced EOC: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol 2000; 76: 157–62

    Article  PubMed  CAS  Google Scholar 

  56. Markman M, Bundy BN, Albert DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the GOG, SWOG and ECOG. J Clin Oncol 2001; 19: 1001–7

    PubMed  CAS  Google Scholar 

  57. Armstrong DK, Bundy BN, Baergen R, et al. Randomized phase III study of intravenous paclitaxel and cisplatin versus intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in optimal stage II epithelial ovarian cancer: A GOG Trial (GOG 172) [abstract]. Proc Am Soc Clin Oncol 2002; 21: 201a

    Google Scholar 

  58. Guastalla JP, Lhomme C, Kerbrat P, et al. Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy. a multicentre study of the French Federation Nationale des Centres de Lutte Contre le Cancer. Ann Oncol 1994; 5: 127–32

    PubMed  CAS  Google Scholar 

  59. Malmstrom H, Simonsen E, Westberg R. A phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients. Gynecol Oncol 1994; 52: 20–5

    Article  PubMed  CAS  Google Scholar 

  60. Fujiwara K, Sakuragi N, Suzuki S, et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol 2003; 90: 637–43

    Article  PubMed  CAS  Google Scholar 

  61. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756–67

    PubMed  CAS  Google Scholar 

  62. Bruckner HW, Wallach R, Cohen CJ, et al. High-dose cisplatin for the treatment of refractory ovarian cancer. Gynecol Oncol 1981; 12: 64–7

    Article  PubMed  CAS  Google Scholar 

  63. Barker GH, Wiltshaw E. Use of high-dose cis-dichlorodiammine platinum (II) [NSC-119875] following failure on previous chemotherapy for advanced carcinoma of the ovary. Br J Obstet Gynaecol 1981; 88: 1192–9

    Article  PubMed  CAS  Google Scholar 

  64. Ozols RF, Ostchega Y, Meyers CE, et al. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 1985; 2: 1246–50

    Google Scholar 

  65. Aghajanian C, Fennelly D, Shapiro F, et al. Phase II study of “dose-dense” high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol 1998; 16: 1852–60

    PubMed  CAS  Google Scholar 

  66. Schilder RJ, Brady MF, Spriggs D, et al. Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a GOG study. Gynecol Oncol 2003; 88: 3–8

    Article  PubMed  CAS  Google Scholar 

  67. Schilder RJ, Gallo JM, Millenson MM, et al. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. J Clin Oncol 2001; 19: 1183–94

    PubMed  CAS  Google Scholar 

  68. Stiff PJ, Vuem-Stone J, Lazarus HM, et al. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med 2000Oct 3; 133(7): 504–15

    PubMed  CAS  Google Scholar 

  69. Legros M, Dauplat J, Fleury J, et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997Apr; 15(4): 1302–8

    PubMed  CAS  Google Scholar 

  70. Cure H, Battista H, Guastalla JP, et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC): preliminary results of a GINECO/FNCLCC/SFGM-TC study [abstract]. Proc Am Soc Clin Oncol 2001, 815a

  71. Hakes TB, Chalas E, Hoskins WJ, et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992; 45: 284–9

    Article  PubMed  CAS  Google Scholar 

  72. Bertelsen K, Jakobsen A, Stroyer J, et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 1993; 49: 30–6

    Article  PubMed  CAS  Google Scholar 

  73. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a SWOG and GOG trial. J Clin Oncol 2003; 21: 2460–5

    Article  PubMed  CAS  Google Scholar 

  74. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000; 5(1): 26–35

    Article  PubMed  CAS  Google Scholar 

  75. Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA 1983; 250: 3072–6

    Article  PubMed  CAS  Google Scholar 

  76. Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1993; 71Suppl. 4: 1559–64

    Article  PubMed  CAS  Google Scholar 

  77. Harries M, Gore M. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol 2002Sep; 3(9): 537–45

    Article  PubMed  CAS  Google Scholar 

  78. Gronlund B, Hogdall C, Hansen HH, et al. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol 2001; 83: 128–34

    Article  PubMed  CAS  Google Scholar 

  79. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361(9375): 2099–106

    Article  PubMed  CAS  Google Scholar 

  80. tenBokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183–93

    PubMed  Google Scholar 

  81. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997Jan; 15(1): 187–92

    PubMed  CAS  Google Scholar 

  82. Niwa Y, Nakanishi T, Kuzuya K, et al. Salvage treatment with docetaxel for recurrent epithelial ovarian cancer. Int J Clin Oncol 2003Dec; 8(6): 343–7

    Article  PubMed  CAS  Google Scholar 

  83. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the 2nd-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14(12): 3056–61

    PubMed  CAS  Google Scholar 

  84. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998Oct; 16(10): 3345–52

    PubMed  CAS  Google Scholar 

  85. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum resistant and platinum-resistant ovarian carcinoma: a GOG Study. J Clin Oncol 1998; 16: 405–10

    PubMed  CAS  Google Scholar 

  86. Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996Oct; 63(1): 89–93

    Article  PubMed  CAS  Google Scholar 

  87. Friedlander M, Millward MJ, Bell D, et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998Dec; 9(12): 1343–5

    Article  PubMed  CAS  Google Scholar 

  88. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997Mar; 15(3): 987–93

    PubMed  CAS  Google Scholar 

  89. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001Jul 15; 19(14): 3312–22

    PubMed  CAS  Google Scholar 

  90. Righetti SC, Delia Torre G, Pilotti S, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996Feb; 56(4): 689–93

    PubMed  CAS  Google Scholar 

  91. Berchuck A, Bast JrRC. p53-Based gene therapy of ovarian cancer: magic bullet? Gynecol Oncol 1995; 59: 169–70

    Article  PubMed  CAS  Google Scholar 

  92. Buller RE, Runnebaum IB, Karlan BY, et al. A phase I/II trial of rAd/p53 (SCH58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 553–66

    Article  PubMed  CAS  Google Scholar 

  93. Buller RE, Shahin MS, Horowitz JA, et al. Long-term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther 2002; 9: 567–72

    Article  PubMed  CAS  Google Scholar 

  94. Berek JS, Schultes BC, Nicodemus CF. Biologic and immunologic therapies for ovarian cancer. J Clin Oncol 2003; 21(10S): 168s–74s

    Article  PubMed  Google Scholar 

  95. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60Suppl. 1: 15–23

    Article  PubMed  CAS  Google Scholar 

  96. Schilder RJ, Kohn E, Sill MW, et al. Phase II trial of gefitinib in patients with recurrent ovarian or primary peritoneal cancer: Gynecology Oncology Group 170C [abstract]. Proc Am Soc Clin Oncol 2003; 22: 1814

    Google Scholar 

  97. Herbst RS. Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 2003; (3 Suppl 7): 34—46

  98. Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the GOG. J Clin Oncol 2003Jan 15; 21(2): 283–90

    Article  PubMed  CAS  Google Scholar 

  99. Burger RA, Sill M, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) [abstract no. 5009]. A Gynecologic Oncology Group (GOG) Study. Proc Am Soc Clin Oncol 2005; 23: 16S

    Google Scholar 

  100. Abramson N, Stokes PK, Luke M, et al. Ovarian and papillary serous peritoneal carcinoma: pilot study with thalidomide. J Clin Oncol 2002; 20: 1147–9

    Article  PubMed  CAS  Google Scholar 

  101. Hirte HW, Vergote IB, Jeffrey J, et al. An international multicentre phase III study of BAY 12-9566 (BAY) versus placebo in patients with advanced ovarian cancer responsive to primary surgery/paclitaxel and platinum containing chemotherapy [abstract no. 832]. Proc Am Soc Clin Oncol 2001; 20: 209a

    Google Scholar 

  102. DiSaia PJ, Bloss JD. Treatment of ovarian cancer: new strategies. Gynecol Oncol 2003; 90: S24–32

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA

    Lainie Martin &  Russell J. Schilder

Authors
  1. Lainie Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Russell J. Schilder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Russell J. Schilder.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martin, L., Schilder, R.J. Front-line treatment of epithelial ovarian cancer. Am J Cancer 4, 221–231 (2005). https://doi.org/10.2165/00024669-200504040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024669-200504040-00002

Keywords

Search

Navigation